Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. Gamucci T, et al. Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7. Cancer Biol Ther. 2019. PMID: 30403909 Free PMC article.
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A, Carlini P, Ruggeri EM, Gamucci T, Pollera CF, De Marco S, Fariello AM, Moscetti L, Gelibter A, Adami E, Sperduti I, Cognetti F. Felici A, et al. Among authors: gamucci t. Cancer Chemother Pharmacol. 2006 Jan;57(1):59-64. doi: 10.1007/s00280-005-0032-5. Epub 2005 Nov 5. Cancer Chemother Pharmacol. 2006. PMID: 16001173 Clinical Trial.
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Gasparini G, Gattuso D, Morabito A, Longo R, Torino F, Sarmiento R, Vitale S, Gamucci T, Mariani L. Gasparini G, et al. Among authors: gamucci t. Oncologist. 2005 Oct;10(9):710-7. doi: 10.1634/theoncologist.10-9-710. Oncologist. 2005. PMID: 16249351 Free article. Clinical Trial.
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Gelibter AJ, Gamucci T, Pollera CF, Di Costanzo F, Nuzzo C, Gabriele A, Signorelli C, Gasperoni S, Ferraresi V, Giannarelli D, Cognetti F, Zeuli M. Gelibter AJ, et al. Among authors: gamucci t. Curr Med Res Opin. 2007 Sep;23(9):2117-23. doi: 10.1185/030079907X226113. Curr Med Res Opin. 2007. PMID: 17651538 Clinical Trial.
A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Pino MS, Gamucci T, Mansueto G, Trapasso T, Narducci F, Giampaolo MA, Fariello AM, Sperduti I, Ceribelli A, Cognetti F. Pino MS, et al. Among authors: gamucci t. Lung Cancer. 2008 Jun;60(3):381-6. doi: 10.1016/j.lungcan.2007.10.027. Epub 2007 Dec 19. Lung Cancer. 2008. PMID: 18068853 Clinical Trial.
153 results